NCT05070247 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 4
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 5
- units
- Participants
- groups
- description
- Participants received TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) for up to 1 year.
- id
- BG000
- title
- Single Agent Dose Escalation: TAK-500 8 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab (TOCI) followed by TAK-500, 8 µg/kg IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG001
- title
- Single Agent Dose Escalation: 1 TOCI + TAK-500 8 µg/kg
- description
- Participants received TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG002
- title
- Single Agent Dose Escalation: TAK-500 16 µg/kg
- description
- Participants received premedication with dexamethasone (DEX) as a single 10 mg IV bolus 1 hour before the administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG003
- title
- Single Agent Dose Escalation: 1 DEX + TAK-500 16 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG004
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 16 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 16 µg/kg, IV infusion, intravenously, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG005
- title
- Single Agent Dose Escalation: 1 TOCI + TAK-500 16 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG006
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 24 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG007
- title
- Single Agent Dose Escalation: 1 TOCI + TAK-500 24 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 40 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG008
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 40 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 60 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG009
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 60 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year, along with TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.
- id
- BG010
- title
- Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 8 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year, along with TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.
- id
- BG011
- title
- Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 16 µg/kg
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.11
- value
- 66.7
- group Id
- BG001
- spread
- 11.53
- value
- 63.0
- group Id
- BG002
- spread
- 5.81
- value
- 70.6
- group Id
- BG003
- spread
- 11.68
- value
- 57.3
- group Id
- BG004
- spread
- 8.89
- value
- 57.0
- group Id
- BG005
- spread
- 7.69
- value
- 64.1
- group Id
- BG006
- spread
- 5.77
- value
- 62.3
- group Id
- BG007
- spread
- 2.83
- value
- 62.0
- group Id
- BG008
- spread
- 7.48
- value
- 52.0
- group Id
- BG009
- spread
- 9.25
- value
- 63.8
- group Id
- BG010
- spread
- 17.27
- value
- 56.2
- group Id
- BG011
- spread
- 6.04
- value
- 66.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 3
- title
- Female
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 2
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 3
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 4
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 2
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 4
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Safety analysis set included participants who had received at least 1 dose, even if incomplete, of any study drug (i.e., TAK-500 or pembrolizumab).
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 3
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 6
- group Id
- BG009
- value
- 4
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 5
- units
- Participants
- groups
- description
- Participants received TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (once every 3 weeks, Q3W) for up to 1 year.
- id
- BG000
- title
- Single Agent Dose Escalation: TAK-500 8 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab (TOCI) followed by TAK-500, 8 µg/kg IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG001
- title
- Single Agent Dose Escalation: 1 TOCI + TAK-500 8 µg/kg
- description
- Participants received TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG002
- title
- Single Agent Dose Escalation: TAK-500 16 µg/kg
- description
- Participants received premedication with dexamethasone (DEX) as a single 10 mg IV bolus 1 hour before the administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG003
- title
- Single Agent Dose Escalation: 1 DEX + TAK-500 16 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle (Q3W) for up to 1 year.
- id
- BG004
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 16 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 16 µg/kg, IV infusion, intravenously, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG005
- title
- Single Agent Dose Escalation: 1 TOCI + TAK-500 16 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG006
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 24 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by TAK-500, 24 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG007
- title
- Single Agent Dose Escalation: 1 TOCI + TAK-500 24 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 40 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG008
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 40 µg/kg
- description
- Participants received premedication with dexamethasone 10 mg orally 12 hours prior and 10 mg IV bolus 1 hour before administration of TAK-500, 60 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year.
- id
- BG009
- title
- Single Agent Dose Escalation: 2 DEX + TAK-500 60 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle or on Days 1 and 22 in a 42-day cycle (Q3W) for up to 1 year, along with TAK-500, 8 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.
- id
- BG010
- title
- Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 8 µg/kg
- description
- Participants received premedication with 8 mg/kg (maximum of 800 mg in a single dose) tocilizumab followed by pembrolizumab 200 mg IV infusion, once on Day 1 of each 21-day treatment cycle, Q3W, for up to 1 year, along with TAK-500, 16 µg/kg, IV infusion, once on Day 1 of each 21-day treatment cycle Q3W, for up to 1 year.
- id
- BG011
- title
- Combination Dose Escalation: 1 TOCI + Pembrolizumab + TAK-500 16 µg/kg
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.11
- value
- 66.7
- group Id
- BG001
- spread
- 11.53
- value
- 63.0
- group Id
- BG002
- spread
- 5.81
- value
- 70.6
- group Id
- BG003
- spread
- 11.68
- value
- 57.3
- group Id
- BG004
- spread
- 8.89
- value
- 57.0
- group Id
- BG005
- spread
- 7.69
- value
- 64.1
- group Id
- BG006
- spread
- 5.77
- value
- 62.3
- group Id
- BG007
- spread
- 2.83
- value
- 62.0
- group Id
- BG008
- spread
- 7.48
- value
- 52.0
- group Id
- BG009
- spread
- 9.25
- value
- 63.8
- group Id
- BG010
- spread
- 17.27
- value
- 56.2
- group Id
- BG011
- spread
- 6.04
- value
- 66.0
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 5
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 3
- title
- Female
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 5
- group Id
- BG011
- value
- 2
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 2
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 3
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 3
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 4
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 2
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 0
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 4
- group Id
- BG009
- value
- 2
- group Id
- BG010
- value
- 4
- group Id
- BG011
- value
- 4
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 1
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- population Description
- Safety analysis set included participants who had received at least 1 dose, even if incomplete, of any study drug (i.e., TAK-500 or pembrolizumab).
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle